▎药明康德内容团队编辑

药明康德内容团队整理

▲如您有任何业务需求，请长按扫描上方二维码，或点击文末“阅读原文/Read more”，即可访问业务对接平台，填写业务需求信息

参考资料：

[1] Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors. Retrieved September 12, 2022, from https://www.mereobiopharma.com/news-and-events/news/2022/september/mereo-biopharma-reports-clinical-update-and-interim-biomarker-analysis-presented-at-esmo-2022/

[2] Regulus Therapeutics Announces Positive Topline Safety and Pharmacokinetic (PK) Data from the Phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Retrieved September 12, 2022, from https://ir.regulusrx.com/2022-09-12-Regulus-Therapeutics-Announces-Positive-Topline-Safety-and-Pharmacokinetic-PK-Data-from-the-Phase-1-Single-Ascending-Dose-SAD-Clinical-Trial-of-RGLS8429-for-the-treatment-of-Autosomal-Dominant-Polycystic-Kidney-Disease-ADPKD

[3] Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine. Retrieved September 12, 2022, from https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=4162209&lang=en-GB&companycode=no-ulti&v=

[4] Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates. Retrieved September 12, 2022, from https://cardiffoncology.investorroom.com/2022-09-12-Cardiff-Oncology-Announces-Plans-for-a-Randomized-Trial-in-Metastatic-Colorectal-Cancer-mCRC-,-Durability-of-Responses-in-Ongoing-Phase-1b-2-Trial-in-mCRC-and-Additional-Business-Updates

[5] Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress. Cardiff Oncology Announces Plans for a Randomized Trial in Metastatic Colorectal Cancer (mCRC), Durability of Responses in Ongoing Phase 1b/2 Trial in mCRC and Additional Business Updates. Retrieved September 10, 2022, from https://www.cabalettabio.com/news-media/press-releases/detail/71/cabaletta-bio-presents-new-interim-data-from-the

[6] Akouos Receives FDA Clearance of its IND Application for AK-OTOF, a Gene Therapy Intended for the Treatment of OTOF-mediated Hearing Loss. Retrieved September 13, 2022, from https://investors.akouos.com/news-releases/news-release-details/akouos-receives-fda-clearance-its-ind-application-ak-otof-gene

[7] Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02. Retrieved September 13, 2022, from https://ir.frtx.com/news/detail/90/fresh-tracks-therapeutics-initiates-multiple-ascending-dose

[8] NGM Bio Presents Updated Preliminary Findings from the Ongoing Phase 1b Dose Escalation Trial of NGM120 in Combination with Gemcitabine and Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer at AACR Special Conference: Pancreatic Cancer. Retrieved September 13, 2022, from https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-presents-updated-preliminary-findings-ongoing-phase-1b

[9] Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine. Retrieved September 13, 2022, from https://ir.vaxxinity.com/news-releases/news-release-details/vaxxinity-announces-first-subjects-dosed-phase-1-clinical-trial

[10] Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers. Retrieved September 15, 2022, from https://investors.alnylam.com/press-release?id=26976

[11] Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer. Retrieved September 15, 2022, from https://investors.imunon.com/news-releases/news-release-details/celsion-completes-enrollment-phase-iii-ovation-2-study-gen-1

[12] Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV. Retrieved September 15, 2022, from https://www.globenewswire.com/news-release/2022/09/15/2516733/0/en/Excision-BioTherapeutics-Doses-First-Participant-in-EBT-101-Phase-1-2-Trial-Evaluating-EBT-101-as-a-Potential-Cure-for-HIV.html

[13] AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial. Retrieved September 14, 2022, from https://investors.avrobio.com/news-releases/news-release-details/avrobio-announces-neuronopathic-mucopolysaccharidosis-type-ii

[14] Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis. Retrieved September 16, 2022, from https://ir.intelliatx.com/news-releases/news-release-details/intellia-and-regeneron-announce-initial-data-cardiomyopathy-arm

[15] CellResearch Corporation (CRC) announces positive results of Phase I study for CorLiCyte®. Retrieved September 16, 2022, from https://www.prnewswire.com/news-releases/cellresearch-corporation-crc-announces-positive-results-of-phase-i-study-for-corlicyte-301626318.html

[16] Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into 

Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement 

with the National Cancer Institute. Retrieved September 16, 2022, from https://marengotx.com/wp-content/uploads/2022/09/Marengo-IND-CRADA-Press-Release-2022.09.14_FINAL-CLEAN.pdf

版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。